MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Articles tagged "Parkinson’s"

  • 2023 International Congress

    Genetic polymorphisms associated with nigrostriatal dopaminergic depletion as measured with [I123]-FP-CIT SPECT in Parkinson’s disease

    S. Castro Labrador, MA. Labrador Espinosa, J. Silva Rodríguez, D. García Solís, P. Mir, MJ. Grothe (Seville, Spain)

    Objective: To conduct a genome-wide association study (GWAS) of striatal [I123]-FP-CIT SPECT signal as endophenotype to explore possible associations between genetic background and nigrostriatal dopaminergic…
  • 2023 International Congress

    Neurophysiological architecture of visual categorization in early Parkinson’s disease with minor hallucinations

    L. Perez-Carasol, S. Martinez-Horta, A. Horta-Barba, A. Puig-Davi, J. Pagonabarraga, J. Kulisevsky (Barcelona, Spain)

    Objective: To explore the neurophysiological dynamics of visual categorization in Parkinson’s disease (PD) with minor hallucinations. Background: Different hypotheses have been proposed for visual hallucinations…
  • 2023 International Congress

    Jumping to Conclusions bias, psychosis and impulsivity in early stages of Parkinson’s disease

    IP. Pachi, VP. Papadopoulos, CK. Koros, AMS. Simitsi, AB. Bougea, MB. Bozi, NP. Papagiannakis, RFP. Soldatos, DK. Kolovou, GP. Pantes, NS. Scarmeas, LAX. Xenaki, GP. Paraskevas, KV. Voumvourakis, SGP. Papageorgiou, KK. Kollias, NS. Stefanis, LS. Stefanis (Athens, Greece)

    Objective: The aim was to explore the correlations between Jumping to Conclusions (JtC) tendency and neuropsychiatric features in patients with early Parkinson’s disease (PD). Background:…
  • 2023 International Congress

    Innovating Clinical Trial Design to Accelerate Assessment of Disease-Modifying Treatments for Parkinson’s: The EJS ACT-PD Initiative

    G. Mills, R. Chapman, S. Collins, R. Ellis-Doyle, C. Gonzalez-Robles, M. Zeissler, O. Bandmann, R. Barker, J. Carpenter, J. Chataway, J. Duffen, S. Gandhi, K. Mcfarthing, S. Mullin, A. Schapira, A. Schrag, C. Carroll, T. Foltynie (London, United Kingdom)

    Objective: To design an optimal multi-arm, multi-stage (MAMS) platform trial for disease-modifying therapies (DMTs) in Parkinson’s disease (PD). Background: The current clinical trials process cannot…
  • 2023 International Congress

    Development of therapeutic substances for the disassembly of α-synuclein aggregates as disease-modifying treatment of synucleinopathies

    A. Willuweit, M. Sevenich, G. Tamgüney, J. Mohrlüder, D. Willbold (Düsseldorf, Germany)

    Objective: Development of high-affinity ligands to α-synuclein (α-syn) for a therapeutic approach aiming for the disassembly of α-syn aggregates as a disease-modifying treatment of synucleinopathies.…
  • 2023 International Congress

    Novel RAB39B stop mutation in patient with typical Early-Onset Parkinson’s disease

    J. Jacobson, C. Piat, O. Ross, R. Savica (Rochester, USA)

    Objective: N/A Background: RAB proteins are small guanosine triphosphatases (GTPases) that are ubiquitous and expressed in all cell types regulating vesicular transport and intracellular membrane…
  • 2023 International Congress

    Screening and Treatment of Depression in Parkinson’s Disease Within Movement Disorders Centers

    C. Marras, D. Weintraub, J. Beck, A. Naito, Z. Meyer, N. Dahodwala, T. Davis, K. Mills, J. Miyasaki, S. Mantri, M. Neault, A. Brown, A. Allen, E. Nelson, H. Liu (Toronto, Canada)

    Objective: Implement depression screening using a validated instrument for people with Parkinson’s (PWP) as part of standard of care in the specialist movement disorders setting…
  • 2023 International Congress

    Zonisamide in advanced Parkinson’s disease: a randomized placebo-controlled study in Egyptian population

    S. Shalash, M. Salim ()

    Objective: To investigate safety and efficacy of ZNS on motor ,non motor symptons and quality of life in advanced PD in egyptian populatiin Background: Zonisamide…
  • 2023 International Congress

    DNA Methylation is associated with gene expression changes in sporadic Parkinson Disease in the PPMI cohort.

    P. Gonzalez-Latapi, B. Bustos, T. Simuni, S. Lubbe, D. Krainc (Chicago, USA)

    Objective: To compare baseline whole blood DNA methylation in unmedicated sporadic  Parkinson Disease (sPD) and healthy control (HC) participants from PPMI. To evaluate whole blood…
  • 2023 International Congress

    Genetic diagnosis of parkinsonian phenotype of Machado Joseph Diseasep (SCA-3) presenting with dopa induced dyskinesia

    D. Chaudhari, A. Mishra, P. Renjen, K. Ahmad, N. Sahu (New Delhi, India)

    Objective: We report a rare type IV parkinsonian phenotype of MJD having a rare genetic mutation. SCA type 3 (SCA3), also known as Machado-Joseph disease…
  • « Previous Page
  • 1
  • …
  • 108
  • 109
  • 110
  • 111
  • 112
  • …
  • 338
  • Next Page »

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Life expectancy with and without Parkinson’s disease in the general population
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • An atypical and interesting feature of Parkinson´s disease
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Effect of marijuana on Essential Tremor: A case report
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Estimation of the 2020 Global Population of Parkinson’s Disease (PD)
  • Patients with Essential Tremor Live Longer than their Relatives
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley